ABL Bio Inc.

KOSDAQ:A298380 Stock Report

Market Cap: ₩1.3t

ABL Bio Future Growth

Future criteria checks 5/6

ABL Bio is forecast to grow earnings and revenue by 50.3% and 25.5% per annum respectively. EPS is expected to grow by 100.9% per annum. Return on equity is forecast to be 9.1% in 3 years.

Key information

50.3%

Earnings growth rate

100.9%

EPS growth rate

Biotechs earnings growth82.2%
Revenue growth rate25.5%
Future return on equity9.1%
Analyst coverage

Low

Last updated28 Aug 2024

Recent future growth updates

No updates

Recent updates

Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Nov 20
Some Confidence Is Lacking In ABL Bio Inc. (KOSDAQ:298380) As Shares Slide 30%

Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

May 29
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?

Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

Feb 26
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?

We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Mar 31
We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth

Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Jan 20
Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?

Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Dec 16
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

KOSDAQ:A298380 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202676,0003,0006,0007,0001
12/31/202582,00011,0005,0005,0001
12/31/202442,000-27,000-15,000-15,0001
9/30/202432,321-49,041-81,451-71,189N/A
6/30/202432,955-40,003-73,541-64,894N/A
3/31/202433,103-38,952-67,776-60,555N/A
12/31/202365,547-2,647-34,206-28,362N/A
9/30/202367,446-7,9511,2524,155N/A
6/30/202397,25423,6085,5348,498N/A
3/31/2023104,80336,1019,86312,230N/A
12/31/202267,3013,20969,74672,132N/A
9/30/202257,9944,35243,64544,605N/A
12/31/20215,332-43,558-41,871-40,605N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A298380 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: A298380 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A298380 is expected to become profitable in the next 3 years.

Revenue vs Market: A298380's revenue (25.5% per year) is forecast to grow faster than the KR market (8.9% per year).

High Growth Revenue: A298380's revenue (25.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A298380's Return on Equity is forecast to be low in 3 years time (9.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 20:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ABL Bio Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.
Jihoon ShinLS Securities Co., Ltd.